RZLT Stock Overview
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Rezolute, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.06 |
| 52 Week High | US$5.01 |
| 52 Week Low | US$1.34 |
| Beta | 2.27 |
| 1 Month Change | 4.04% |
| 3 Month Change | 23.72% |
| 1 Year Change | -47.31% |
| 3 Year Change | -61.53% |
| 5 Year Change | -95.41% |
| Change since IPO | -99.69% |
Recent News & Updates
Shareholder Returns
| RZLT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.0% | 1.6% | 3.1% |
| 1Y | -47.3% | 10.5% | -8.5% |
Return vs Industry: RZLT underperformed the US Biotechs industry which returned 10.5% over the past year.
Return vs Market: RZLT underperformed the US Market which returned -8.5% over the past year.
Price Volatility
| RZLT volatility | |
|---|---|
| RZLT Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: RZLT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: RZLT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 42 | Nevan Elam | https://www.rezolutebio.com |
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company’s lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema.
Rezolute, Inc. Fundamentals Summary
| RZLT fundamental statistics | |
|---|---|
| Market Cap | US$73.47m |
| Earnings (TTM) | -US$43.05m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.8x
P/E RatioIs RZLT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RZLT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$43.06m |
| Earnings | -US$43.05m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.17 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RZLT perform over the long term?
See historical performance and comparison